Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 2/20 | 0.41 |
| ▸ | ADH1C | P00326 | 2/20 | 0.41 |
| ▸ | ADH1A | P07327 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1911407 | 0.86 | ADH1B (0.35) | ADH1BADH1CADH1ACTSK | |
| SCHEMBL2701598 | 0.80 | CTSK (0.34) | ADH1BADH1CADH1ACTSK | |
| SCHEMBL277866 | 0.80 | ADH1B (0.48) | ADH1BADH1CADH1A | |
| SCHEMBL14115915 | 0.74 | ADH1B (0.42) | ADH1BADH1CADH1A | |
| SCHEMBL2702682 | 0.72 | ADH1B (0.40) | ADH1BADH1CADH1A | |
| SCHEMBL1911356 | 0.72 | ADH1B (0.40) | ADH1BADH1CADH1A | |
| SCHEMBL2700414 | 0.69 | ADH1B (0.37) | ADH1BADH1CADH1A | |
| SCHEMBL28559210 | 0.69 | ADH1B (0.46) | ADH1BADH1CADH1A | |
| SCHEMBL31670211 | 0.69 | CTSK (0.37) | CTSK | |
| SCHEMBL23378342 | 0.68 | ADH1B (0.46) | ADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331545-A1 | REGULATOR FOR SIGNALING TOLL-LIKE RECEPTOR, WHICH COMPRISES CATHEPSIN INHIBITOR AS ACTIVE INGREDIENT | NIPPON CHEMIPHAR CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331545-A1 | REGULATOR FOR SIGNALING TOLL-LIKE RECEPTOR, WHICH COMPRISES CATHEPSIN INHIBITOR AS ACTIVE INGREDIENT | TLR1, TLR7, TLR6 | ADH1B 4592/4885ADH1C 4663/4885ADH1A 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.